Despite a downturn in dealmaking, as companies seek to secure growth through innovation, M&A will need to take a central strategic role.
- 2022 was a slow year for dealmaking in the life sciences but the final quarter saw a major uptick.
- Conditions are right for major M&A with record firepower and a wealth of targets for 2023.
- Companies will focus on the right strategic deals, which will include access to data and new technologies to secure future growth.
- Click here to view the full report - https://go.ey.com/3CCUYm7
Ruby Sharoon-Khan (firstname.lastname@example.org)